James C. Foster Buys 6,075 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) CEO James C. Foster acquired 6,075 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Charles River Laboratories International Trading Up 0.5 %

Charles River Laboratories International stock opened at $163.11 on Friday. The stock has a market cap of $8.34 billion, a PE ratio of 1,087.39, a P/E/G ratio of 4.54 and a beta of 1.37. The stock has a 50-day moving average price of $172.84 and a 200 day moving average price of $188.09. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $275.00. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same period last year, the company earned $2.46 EPS. The firm’s quarterly revenue was down 1.1% on a year-over-year basis. Equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Institutional Trading of Charles River Laboratories International

Hedge funds have recently added to or reduced their stakes in the business. Versant Capital Management Inc boosted its stake in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after buying an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. boosted its stake in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares during the last quarter. Assetmark Inc. boosted its stake in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares during the last quarter. Optiver Holding B.V. acquired a new stake in Charles River Laboratories International in the 4th quarter worth about $37,000. Finally, GeoWealth Management LLC boosted its stake in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after buying an additional 190 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. UBS Group reaffirmed a “neutral” rating and set a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Barclays lowered their target price on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 18th. Evercore ISI upped their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Finally, The Goldman Sachs Group lowered their target price on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $195.71.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).